Kazazian Asset Management LLC Buys Shares of 133,183 Indivior PLC (NASDAQ:INDV)

Kazazian Asset Management LLC acquired a new position in shares of Indivior PLC (NASDAQ:INDV - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 133,183 shares of the company's stock, valued at approximately $1,706,000. Indivior comprises about 1.3% of Kazazian Asset Management LLC's portfolio, making the stock its 20th biggest holding. Kazazian Asset Management LLC owned about 0.10% of Indivior as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Indivior in the fourth quarter valued at about $56,000. Stifel Financial Corp bought a new stake in shares of Indivior in the third quarter valued at about $100,000. Melqart Asset Management UK Ltd bought a new stake in shares of Indivior in the third quarter valued at about $132,000. Jane Street Group LLC bought a new stake in shares of Indivior in the third quarter valued at about $180,000. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of Indivior in the third quarter valued at about $294,000. Institutional investors own 60.33% of the company's stock.

Indivior Trading Up 1.4 %

NASDAQ INDV traded up $0.14 during trading on Friday, hitting $9.82. 683,341 shares of the company's stock were exchanged, compared to its average volume of 627,394. The company has a market cap of $1.35 billion, a PE ratio of -28.06 and a beta of 0.82. Indivior PLC has a fifty-two week low of $7.33 and a fifty-two week high of $22.53. The stock's 50 day moving average price is $10.41 and its two-hundred day moving average price is $10.41.

Remove Ads

Indivior (NASDAQ:INDV - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported $0.32 EPS for the quarter, hitting the consensus estimate of $0.32. The firm had revenue of $298.00 million during the quarter, compared to the consensus estimate of $262.35 million. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. Analysts forecast that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

INDV has been the subject of several recent analyst reports. Piper Sandler cut their price objective on shares of Indivior from $16.00 to $13.00 and set an "overweight" rating for the company in a research report on Thursday, March 6th. RODMAN&RENSHAW raised shares of Indivior to a "strong-buy" rating in a research report on Tuesday, January 28th. Finally, Rodman & Renshaw initiated coverage on shares of Indivior in a research report on Tuesday, January 28th. They set a "buy" rating and a $16.00 price objective for the company.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.